FDA delays Ravicti decision

FDA extended the PDUFA date by three months for an NDA from Hyperion Therapeutics Inc. (NASDAQ:HPTX) for Ravicti glycerol phenylbutyrate for the management of chronic urea cycle disorders in patients ...